12 recruiting. 12 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 12 |
| Phase 2 | 8 | Recruiting 8 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome ION337 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 32 | 2026-05-21 | 2026-09-03 |
| Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. Antisense oligonucleotide treatment (ASO) - GNAO1, Epilepsy | Phase 1 / Phase 2 | Recruiting | Pirogov Russian National Research Medical University | 5 | 2025-09-09 | 2026-01-23 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients SIF001, Placebo - Epilepsy, Healthy Volunteer | Phase 1 | Recruiting | Suninflam Inc | 88 | 2025-06-16 | 2026-06-15 |
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease ION283 - Lafora Disease | Phase 1 / Phase 2 | Recruiting | Berge Minassian | 10 | 2024-12-03 | 2025-12-18 |
| Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy Mangafodipir, Gadolinium - Epilepsy | Phase 1 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2024-11-19 | 2026-10-29 |
| A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) NRTX-1001 - Epilepsy, Temporal Lobe | Phase 1 / Phase 2 | Recruiting | Neurona Therapeutics | 10 | 2024-11-14 | 2026-01-07 |
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy NaviFUS System - Drug Resistant Epilepsy, Epilepsy | Phase 1 / Phase 2 | Recruiting | NaviFUS Corporation | 8 | 2024-09-13 | 2026-09-15 |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy AAV9-hSyn1-miGRIK2 - Mesial Temporal Lobe Epilepsy | Phase 1 / Phase 2 | Recruiting | UniQure Biopharma B.V. | 12 | 2024-06-12 | 2026-08-24 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Encoded Therapeutics | 113 | 2024-05-14 | 2026-10-23 |
| Microelectrode Recordings From the Vagus Nerve in Awake Humans VNS stimulation and intraneural recordings, Record multi-unit activity from intraneural sites - Epilepsy | Phase 1 | Recruiting | University of Minnesota | 60 | 2024-04-01 | 2026-04-20 |
| Glutamate Inhibitors in Glioblastoma Gabapentin, Sulfasalazine, Memantine - Glioblastoma | Phase 1 / Phase 2 | Recruiting | University of Zurich | 120 | 2023-01-01 | 2024-05-10 |
| Understanding Ketamine's Dissociative Effects (KD Study) Ketamine - Epilepsy | Phase 1 | Recruiting | Stanford University | 20 | 2021-07-26 | 2026-04-22 |
Epilepsies, Myoclonic (2) · Seizures (2) · Drug Resistant Epilepsy (1) · Epilepsy, Temporal Lobe (1) · Epileptic Syndromes (1) · Generalized Epilepsy With Febrile Seizures Plus, Type 2 (1) · Glioblastoma (1) · Hippocampal Sclerosis (1) · Hyperkinesis (1) · Lafora Disease (1)
Brain Diseases (12) · Central Nervous System Diseases (12) · Nervous System Diseases (12) · Epileptic Syndromes (4) · Epilepsy, Generalized (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Astrocytoma (1) · Congenital Abnormalities (1) · Dyskinesias (1) · Epilepsies, Myoclonic (1) · Epilepsies, Partial (1)
Gabapentin (1) · Gadolinium (1) · Ketamine (1) · Memantine (1) · N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid (1) · Radiotherapy (1) · Sulfasalazine (1) · Temozolomide (1)
Berge Minassian (1) · Encoded Therapeutics (1) · Ionis Pharmaceuticals, Inc. (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · NaviFUS Corporation (1) · Neurona Therapeutics (1) · Pirogov Russian National Research Medical University (1) · Stanford University (1) · Suninflam Inc (1) · UniQure Biopharma B.V. (1) · University of Minnesota (1) · University of Zurich (1)
United States (10) · Australia (1) · Canada (1) · Russia (1) · Switzerland (1) · United Kingdom (1)
Berge Minassian, MD (1) · Eduardo Dunayevich, MD (1) · Elena D Belousova, Prof (1) · Hans-Georg Wirsching, MD (1) · John Osborn (1) · Karl Deisseroth, MD, PhD (1) · Salvador Rico, M.D., Ph.D (1) · Sara K Inati, M.D. (1) · Vaughan G Macefield, PhD (1)